LeMaitre Vascular (NASDAQ:LMAT) Updates Q2 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its second quarter earnings guidance on Thursday. The company provided EPS guidance of $0.45-0.50 for the period, compared to the consensus EPS estimate of $0.44. The company issued revenue guidance of $53.7-56.1 million, compared to the consensus revenue estimate of $54.29 million. LeMaitre Vascular also updated its FY24 guidance to $1.73-1.84 EPS.

LeMaitre Vascular Stock Down 0.0 %

Shares of LMAT traded down $0.01 during mid-day trading on Thursday, reaching $66.77. The company’s stock had a trading volume of 176,660 shares, compared to its average volume of 114,195. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 49.28, a price-to-earnings-growth ratio of 2.79 and a beta of 0.88. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $74.64. The business has a fifty day moving average of $65.56 and a 200 day moving average of $58.47.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. The business had revenue of $48.90 million for the quarter, compared to the consensus estimate of $49.01 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. LeMaitre Vascular’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.25 earnings per share. On average, analysts predict that LeMaitre Vascular will post 1.66 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, March 13th. This represents a $0.64 annualized dividend and a dividend yield of 0.96%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s dividend payout ratio (DPR) is 47.76%.

Analysts Set New Price Targets

Several equities analysts have commented on LMAT shares. KeyCorp started coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a sector weight rating for the company. Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and raised their target price for the company from $59.00 to $75.00 in a report on Friday, April 26th. Barrington Research raised their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an outperform rating in a research report on Wednesday, February 28th. Finally, StockNews.com cut LeMaitre Vascular from a buy rating to a hold rating in a report on Tuesday, April 16th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of Moderate Buy and an average price target of $69.33.

Insider Buying and Selling

In other news, Director John A. Roush sold 7,500 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total transaction of $517,500.00. Following the transaction, the director now owns 2,278 shares in the company, valued at $157,182. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $157,182. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at $358,357.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 114,036 shares of company stock worth $7,873,749. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.